144 related articles for article (PubMed ID: 33887741)
21. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
[TBL] [Abstract][Full Text] [Related]
22. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
[TBL] [Abstract][Full Text] [Related]
23. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
[TBL] [Abstract][Full Text] [Related]
24. Association between hyporesponsiveness to erythropoiesis-stimulating agents and risk of brain hemorrhage in patients undergoing hemodialysis: the Q-Cohort Study.
Uchida Y; Nakano T; Kitamura H; Taniguchi M; Tsuruya K; Kitazono T
Clin Exp Nephrol; 2023 Jan; 27(1):79-88. PubMed ID: 36100804
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
[TBL] [Abstract][Full Text] [Related]
26. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
27. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
Pan S; Zhao DL; Li P; Sun XF; Zhou JH; Song KK; Wang Y; Miao LN; Ni ZH; Lin HL; Liu FY; Li Y; He YN; Wang NS; Wang CL; Zhang AH; Chen MH; Yang XP; Deng YY; Shao FM; Fu SX; Fang JA; Cai GY; Chen XM
Blood Purif; 2022; 51(2):171-181. PubMed ID: 34175850
[TBL] [Abstract][Full Text] [Related]
28. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.
Usui T; Zhao J; Fuller DS; Hanafusa N; Hasegawa T; Fujino H; Nomura T; Zee J; Young E; Robinson BM; Nangaku M
Nephrology (Carlton); 2021 Jan; 26(1):46-53. PubMed ID: 32743932
[TBL] [Abstract][Full Text] [Related]
29. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
[TBL] [Abstract][Full Text] [Related]
30. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
31. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial.
Lim JH; Jeon Y; Yook JM; Choi SY; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
Sci Rep; 2020 Sep; 10(1):16062. PubMed ID: 32994531
[TBL] [Abstract][Full Text] [Related]
32. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Ogawa T; Nitta K
Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
[TBL] [Abstract][Full Text] [Related]
33. Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure - Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry.
Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Sato K; Sai S; Sugano A; Obara K; Aonuma K
Circ J; 2017 Oct; 81(11):1662-1669. PubMed ID: 28592726
[TBL] [Abstract][Full Text] [Related]
34. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
[TBL] [Abstract][Full Text] [Related]
35. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan.
Hsu WH; Sue SP; Liang HL; Tseng CW; Lin HC; Wen WL; Lee MY
Front Public Health; 2021; 9():711723. PubMed ID: 34604157
[No Abstract] [Full Text] [Related]
37. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.
Hara A; Koshino Y; Kurokawa Y; Shinozaki Y; Miyake T; Kitajima S; Toyama T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Nakamura H; Wada T
Clin Exp Nephrol; 2020 Jan; 24(1):88-95. PubMed ID: 31502102
[TBL] [Abstract][Full Text] [Related]
38. Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients.
Yajima T; Yajima K; Takahashi H
PLoS One; 2021; 16(1):e0245625. PubMed ID: 33449974
[TBL] [Abstract][Full Text] [Related]
39. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
40. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]